A5035935164- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Impact on Reproduction
- Long-Term Effects of COVID-19
- Transplantation: Methods and Outcomes
- Immunodeficiency and Autoimmune Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Cardiac Ischemia and Reperfusion
- Drug-Induced Adverse Reactions
- Parvovirus B19 Infection Studies
- Chronic Lymphocytic Leukemia Research
- HIV/AIDS drug development and treatment
- Infectious Aortic and Vascular Conditions
- Cardiac Structural Anomalies and Repair
- Hematopoietic Stem Cell Transplantation
- Bacillus and Francisella bacterial research
- Mechanical Circulatory Support Devices
- Cytomegalovirus and herpesvirus research
- Animal Virus Infections Studies
- Infective Endocarditis Diagnosis and Management
- Tuberculosis Research and Epidemiology
- Herpesvirus Infections and Treatments
- SARS-CoV-2 detection and testing
University Health Network
2022-2024
University of Toronto
2023-2024
Hospital Universitario Quirónsalud Madrid
2024
Peter MacCallum Cancer Centre
2022
Université de Montréal
2022
The University of Melbourne
2022
Royal Prince Alfred Hospital
2022
Data regarding coronavirus disease 2019 (COVID-19) outcomes in solid organ transplant recipients (SOTr) across severe acute respiratory syndrome 2 (SARS-CoV-2) waves, including the impact of different measures, are lacking. This cohort study, conducted from March 2020 to May 2023 Toronto, Canada, aimed analyze COVID-19 1975 SOTr various SARS-CoV-2 waves and assess preventive treatment measures. The primary outcome was COVID-19, defined as requiring supplemental oxygen, with secondary...
Solid organ transplant (SOT) recipients are at high risk for complications from coronavirus disease 2019 (COVID-19) and vaccine breakthrough infections common. We determined the effectiveness of ≥3 doses mRNA early monoclonal antibody therapy in reducing severity against Omicron (B.1.1.529) variant.Prospective cohort study consecutive SOT with severe acute respiratory syndrome 2 (SARS-CoV-2) infection referred to our center who were followed least 30 days. The primary outcome was...
Background. Solid organ transplant recipients face an increased risk of severe coronavirus disease 2019 (COVID-19) and are vulnerable to repeat acute respiratory syndrome 2 (SARS-CoV-2) infections. In nonimmunocompromised individuals, SARS-CoV-2 reinfections milder likely because cross-protective immunity. We sought determine whether reinfection exhibits manifestations than primary infection in recipients. Methods. Using a large, prospective cohort adult patients with COVID-19, we identified...
Solid organ transplant (SOT) recipients are at high risk for complications from coronavirus disease 2019 (COVID-19). Vaccination may mitigate this risk; however, immunogenicity appears to be significantly impaired, with reports of increased breakthrough infection. It is unknown if vaccine infections milder or as severe in unvaccinated patients.
<h3>Background:</h3> Severe COVID-19 appears to disproportionately affect people who are immunocompromised, although Canadian data in this context limited. We sought determine factors associated with severe outcomes among recipients of organ transplants across Canada. <h3>Methods:</h3> performed a multicentre, prospective cohort study all solid from 9 transplant programs Canada received diagnosis March 2020 November 2021. Data were analyzed risk for oxygen requirement and other metrics...
Abstract Immunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral cellular immune responses Omicron BA.1 in organ transplant across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, Omicron-BA.1, -BA.2, Delta variants. also measure poly-and monofunctional T-cell ancestral SARS-CoV-2 peptide pools. identify that partially or fully-vaccinated recipients after infection with have the...
Allogeneic hematopoietic stem cell transplantation (HSCT) recipients are susceptible to severe outcomes of Coronavirus disease 2019 (COVID-19). Most guidelines recommend a fourth dose (ie, booster) COVID-19 vaccine reduce the infection risk, and observational studies needed determine immunogenicity safety booster in this population. The primary outcome was quantitative anti-receptor-binding domain (RBD) antibody titers after vaccine. secondary included adverse effects all-cause mortality....
There are few interventional studies using CMV cell-mediated immunity (CMI) to guide antiviral prophylaxis. We assessed the Quantiferon-CMV (QTF-CMV) assay prophylaxis duration in high-risk organ transplant recipients.
ABSTRACT Background A considerable knowledge gap exists in predicting severe Pneumocystis pneumonia (PCP) outcomes following PCP diagnosis. Methods In this retrospective cohort, we studied immunocompromised patients with admitted to 5 University Health Network centers Canada (2011–2022). The study outcome included PCP, a composite of 21‐day ICU admission or 28‐day all‐cause mortality. Adjusted odds ratios (aOR) estimated the association between and comorbidities as well clinical laboratory...
<h3>Résumé</h3> <h3>Contexte:</h3> La forme grave de COVID-19 semble affecter manière disproportionnée les gens immunovulnérables, même si données canadiennes dans ce contexte sont limitées. Nous avons voulu déterminer quels facteurs associés aux paramètres la chez receveurs transplantations au Canada. <h3>Méthodes:</h3> procédé à une étude cohorte multicentrique prospective regroupant tous d’une transplantation d’organe plein ayant reçu un diagnostic suivis 9 programmes Canada entre mars...